Related references
Note: Only part of the references are listed.PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer
Nicoletta D'Alessandris et al.
VIRCHOWS ARCHIV (2021)
HPV73 a nonvaccine type causes cervical cancer
Sergio M. Amaro-Filho et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
Alessandro D. Santin et al.
GYNECOLOGIC ONCOLOGY (2020)
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix
Georgia Karpathiou et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma
Masako Ishikawa et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
Kunihiro Asanuma et al.
SCIENTIFIC REPORTS (2020)
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
Claire F. Friedman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva et al.
LANCET ONCOLOGY (2019)
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer
Xiaobin Gu et al.
CANCER CELL INTERNATIONAL (2019)
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Elia D. Tait Wojno et al.
IMMUNITY (2019)
CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase Ill, randomized, double-blind, multicenter study.
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Ronnie Shapira-Frommer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.
Kamran A. Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer
Angela M. Hong et al.
ORAL ONCOLOGY (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Tumor-associated CD204+ M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma
Asuka Kawachi et al.
CANCER SCIENCE (2018)
Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization
Hyeyoon Chang et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2018)
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer
Peixin Dong et al.
ONCOGENE (2018)
PD-L1 receptor expression in vulvar carcinomas is HPV-independent
M. Choschzick et al.
VIRCHOWS ARCHIV (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer
Ying Meng et al.
JOURNAL OF CANCER (2018)
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer
Jayati Chakrabarti et al.
Oncotarget (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Radiotherapy and checkpoint inhibitors: a winning new combination?
Eric C. Ko et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort
N.H. Segal et al.
ANNALS OF ONCOLOGY (2017)
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Julie George et al.
CLINICAL CANCER RESEARCH (2017)
Potential immunotherapy targets in recurrent cervical cancer
Kari L. Ring et al.
GYNECOLOGIC ONCOLOGY (2017)
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
Wen Yang et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2017)
Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status
Sarah R. Ottenhof et al.
JOURNAL OF UROLOGY (2017)
Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma
Bo Zhang et al.
MEDICAL ONCOLOGY (2017)
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
Emeka K. Enwere et al.
MODERN PATHOLOGY (2017)
Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis
Yongxun Zhuan-Sun et al.
ONCOTARGETS AND THERAPY (2017)
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Linda Tran et al.
CANCER IMMUNOLOGY RESEARCH (2017)
A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers
Po-Lin Lin et al.
CANCER MEDICINE (2017)
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy
Dan Ou et al.
ONCOIMMUNOLOGY (2017)
Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines
Chaoya Ma et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2017)
A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.
Jyoti Mayadev et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.
Linda R. Duska et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis
Changjun Wang et al.
BREAST JOURNAL (2017)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2017)
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Opal L. Reddy et al.
DIAGNOSTIC PATHOLOGY (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Changing paradigms in the systemic treatment of advanced cervical cancer
Krista S. Pfaendler et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2016)
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies
P. Vici et al.
EXPERT REVIEW OF VACCINES (2016)
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
John R. Webb et al.
GYNECOLOGIC ONCOLOGY (2016)
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
Naoki Takahashi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Human papillomavirus E6 and E7 oncoproteins affect the expression of cancer-related microRNAs: additional evidence in HPV-induced tumorigenesis
Maria Vincenza Chiantore et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
Zhifang Chen et al.
MEDIATORS OF INFLAMMATION (2016)
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
A. Marijne Heeren et al.
MODERN PATHOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
Zhongfu Mo et al.
ONCOLOGY LETTERS (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
Angela M. Hong et al.
ONCOTARGET (2016)
A Phase I study of indoximod in patients with advanced malignancies
Hatem H. Soliman et al.
ONCOTARGET (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva
Brooke E. Howitt et al.
JAMA ONCOLOGY (2016)
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report
Misako Nagasaka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
Chunbo He et al.
EMBO MOLECULAR MEDICINE (2015)
MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin
Dianzhong Geng et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2015)
Adoptive T-Cell Therapy Is a Promising Salvage Approach for Advanced or Recurrent Metastatic Cervical Cancer
Emese Zsiros et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Louisa Mezache et al.
MODERN PATHOLOGY (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area
A. Marijne Heeren et al.
ONCOTARGET (2015)
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
Michael Platten et al.
FRONTIERS IN IMMUNOLOGY (2015)
CD14+ macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: A new therapeutic lead?
A. Marijne Heeren et al.
ONCOIMMUNOLOGY (2015)
Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
Jill Gilbert et al.
Journal for ImmunoTherapy of Cancer (2015)
Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
Robert L Ferris et al.
Journal for ImmunoTherapy of Cancer (2015)
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
Nicolas L Losa et al.
Journal for ImmunoTherapy of Cancer (2015)
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Yong Wha Moon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
The Targeting of Indoleamine 2,3 Dioxygenase -Mediated Immune Escape in Cancer
Trine Zeeberg Iversen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
Ian-James Malm et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
Kavitha Gowrishankar et al.
PLOS ONE (2015)
High and Interrelated Rates of PD-L1(+)CD14(+) Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer
A. Marijne Heeren et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Kohei Shitara et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer.
Yasuhide Yamada et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC)
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
Haruo Iguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Effects of Bevacizumab: Killing Two Birds with One Stone
Yasir Y. Elamin et al.
CANCER MICROENVIRONMENT (2015)
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
Anke Vanderstraeten et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Programmed death-1 (PD-1)-dependent functional impairment of CD4+ T cells in recurrent genital papilloma
Dong-Yeop Chang et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2014)
Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Ruey-Shyang Soong et al.
CLINICAL CANCER RESEARCH (2014)
Hypoxia in the intestine or solid tumors: A beneficial or deleterious alarm signal?
Hussein Shehade et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Glassy cell carcinoma of the cervix: A systematic review and meta-analysis
Camilla Guitarte et al.
GYNECOLOGIC ONCOLOGY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
MicroRNAs in Cervical Cancer: Evidences for a miRNA Profile Deregulated by HPV and Its Impact on Radio-Resistance
Abraham Pedroza-Torres et al.
MOLECULES (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Integrating canonical and metabolic signalling programmes in the regulation of T cell responses
Kristen N. Pollizzi et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia
Wen Yang et al.
IMMUNOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
Mikayel Mkrtichyan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Role of the PD-1 Pathway in the Immune Response
L. V. Riella et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression
Lynda J. Hatam et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Treatment of Cervical Intraepithelial Neoplasia With Topical Imiquimod A Randomized Controlled Trial
Christoph Grimm et al.
OBSTETRICS AND GYNECOLOGY (2012)
Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
Nikolaos Patsoukis et al.
SCIENCE SIGNALING (2012)
Tumor metabolism as modulator of immune response and tumor progression
Eva Gottfried et al.
SEMINARS IN CANCER BIOLOGY (2012)
MicroRNAs in the p53 network: micromanagement of tumour suppression
Heiko Hermeking
NATURE REVIEWS CANCER (2012)
Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
Mikayel Mkrtichyan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
Mi-Young Song et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
S. Daayana et al.
BRITISH JOURNAL OF CANCER (2010)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Immunosenescence and cancer (Reprinted form Journal of Geriatric Oncology vol 1, pg 22-6, 2010)
Graham Pawelec et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia
Annelinde Terlou et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Immunoreceptor tyrosine-based inhibition motifs:: a quest in the past and future
Marc Daeron et al.
IMMUNOLOGICAL REVIEWS (2008)
Oxidative stress regulates expression of VEGFR1 in myeloid cells:: Link to tumor-induced immune suppression in renal cell carcinoma
Sergei Kusmartsev et al.
JOURNAL OF IMMUNOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
The MAPK signalling pathways and colorectal cancer
JY Fang et al.
LANCET ONCOLOGY (2005)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine
YF He et al.
JOURNAL OF IMMUNOLOGY (2004)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
